These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 18258586)

  • 41. Erythropoietic-stimulating agents (ESAs): new safety warning.
    Zarowitz BJ
    Geriatr Nurs; 2007; 28(3):148-50. PubMed ID: 17561012
    [No Abstract]   [Full Text] [Related]  

  • 42. Antithrombotic management in patients with prosthetic valves: a comparison of American and European guidelines.
    Butchart EG
    Heart; 2009 Mar; 95(5):430-6. PubMed ID: 19218268
    [No Abstract]   [Full Text] [Related]  

  • 43. Is antithrombotic prophylaxis required in cancer patients with central venous catheters? Yes for special patient groups.
    Huisman MV
    J Thromb Haemost; 2006 Jan; 4(1):10-3. PubMed ID: 16409442
    [No Abstract]   [Full Text] [Related]  

  • 44. Prophylaxis of upper limb deep vein thrombosis in cancer patients with central vein catheter.
    Verso M; Agnelli G
    Thromb Haemost; 2008 Jul; 100(1):167-8. PubMed ID: 18612558
    [No Abstract]   [Full Text] [Related]  

  • 45. Managing dysfunctional central venous access devices: a practical approach to urokinase thrombolysis.
    Kumwenda M; Dougherty L; Spooner H; Jackson V; Mitra S; Inston N
    Br J Nurs; 2018 Jan; 27(2):S4-S10. PubMed ID: 29368572
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Alteplase for stroke. American Heart Association explains how guidelines were formulated.
    Faxon D
    BMJ; 2002 Jun; 324(7353):1581; author reply 1581. PubMed ID: 12092606
    [No Abstract]   [Full Text] [Related]  

  • 47. Keeping the lines open.
    Weatherill K
    Nurs Stand; 1999 Sep 15-21; 13(52):41-2. PubMed ID: 10693511
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Safety and outcome after thrombolysis in stroke patients with mild symptoms.
    Köhrmann M; Nowe T; Huttner HB; Engelhorn T; Struffert T; Kollmar R; Saake M; Doerfler A; Schwab S; Schellinger PD
    Cerebrovasc Dis; 2009; 27(2):160-6. PubMed ID: 19092237
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Antithrombotic prophylaxis and central venous catheters in onco-hematological patients].
    Iturbe T; De Gregorio MA; Serrablo A; Cornudella R
    Sangre (Barc); 1999 Dec; 44(6):491. PubMed ID: 10822767
    [No Abstract]   [Full Text] [Related]  

  • 50. The use of alteplase for restoring patency to occluded central venous access devices in infants and children.
    Fisher AA; Deffenbaugh C; Poole RL; Garcia M; Kerner JA
    J Infus Nurs; 2004; 27(3):171-4. PubMed ID: 15118455
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Minimising central venous catheter-associated bloodstream infections--'Matching Michigan' in England.
    Richardson A
    Nurs Crit Care; 2009; 14(3):105-6. PubMed ID: 19366405
    [No Abstract]   [Full Text] [Related]  

  • 52. The 8(th) American College of Chest Physicians Guidelines - a perspective on venous thromboembolism guidelines.
    Squizzato A; Ageno W
    Thromb Haemost; 2009 Jan; 101(1):31-5. PubMed ID: 19132186
    [No Abstract]   [Full Text] [Related]  

  • 53. Alteplase for central catheter clearance: 1 mg/mL versus 2 mg/2 mL.
    Fink JM; Capozzi DL; Shermock KM; Militello MA; Hutson TE; Kalaycio ME; Bolwell BJ
    Ann Pharmacother; 2004 Feb; 38(2):351-2. PubMed ID: 14742778
    [No Abstract]   [Full Text] [Related]  

  • 54. Safety and efficacy of the POP technique for restoring patency to occluded PIC catheters.
    Fetzer SJ; Manning GP
    Appl Nurs Res; 2004 Nov; 17(4):297-300. PubMed ID: 15573339
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Managing vascular access device occlusions, Part. 1.
    Hadaway LC
    Nursing; 2000 Jul; 30(7):20. PubMed ID: 10983093
    [No Abstract]   [Full Text] [Related]  

  • 56. Alfimeprase to succeed Genentech's alteplase?
    Vastag B
    Nat Biotechnol; 2006 Aug; 24(8):875-6. PubMed ID: 16900112
    [No Abstract]   [Full Text] [Related]  

  • 57. The CARI guidelines. Pharmacological approaches to preventing vascular access failure.
    Polkinghorne K;
    Nephrology (Carlton); 2008 Jul; 13 Suppl 2():S12-6. PubMed ID: 18713119
    [No Abstract]   [Full Text] [Related]  

  • 58. Alteplase as hemodialysis catheter locking solution and spurious hyperphosphatemia.
    Sombolos K; Bamichas G; Hatsiou V; Fragidis S; Rizos A; Natse T; Fytili C
    J Vasc Access; 2011; 12(3):269. PubMed ID: 21218384
    [No Abstract]   [Full Text] [Related]  

  • 59. Getting to the heart of the NPSGs.
    Roberts D
    Medsurg Nurs; 2006 Jun; 15(3):127-8. PubMed ID: 16817294
    [No Abstract]   [Full Text] [Related]  

  • 60. Probing the safety of central venous catheters.
    Murray EW
    Am J Nurs; 1993 May; 93(5):72, 75-6. PubMed ID: 8488905
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.